Home | Quoin Pharmaceuticals
4 days ago · We are relentlessly focused on developing therapeutic products to address a range of rare diseases and we are humbled and inspired every day by the courage of patients, their families and their care teams. Patients are at the center of everything we do.
Quoin Pharmaceuticals Announces Further Positive Clinical Data …
4 days ago · ASHBURN, Va., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and ...
Company | Quoin Pharmaceuticals
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is a clinical stage specialty pharmaceutical company focused on the development and commercialization of therapeutic drug products that treat rare and orphan diseases.
Quoin Pharmaceuticals, Ltd. (QNRX) - Yahoo Finance
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases.
Pipeline - Quoin Pharmaceuticals
Jan 6, 2025 · Our pipeline comprises four unique products that collectively have the potential to target a broad number of indications, including Netherton Syndrome, Scleroderma, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa and others.
Quoin Pharmaceuticals Announces Additional Positive Interim …
Jan 6, 2025 · Quoin Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in ...
QRX003 Shows Promise in Pediatric Patients with Netherton …
4 days ago · More data has been announced from Quoin Pharmaceuticals regarding positive results from the Investigator Pediatric Study QRX003 trial for the treatment of Netherton Syndrome. 1 Just last week, Quoin shared promising interim results from its ongoing, open-label study in patients 14 years of age and older. 2 The comparative study saw significant improvements in skin appearance based on all ...
Quoin Pharmaceuticals Announces Positive Interim Data from
ASHBURN, Va., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and...
Quoin Pharmaceuticals Reports Positive Interim Clinical Data
Jan 6, 2025 · Quoin Pharmaceuticals Ltd. announced positive interim clinical data from an ongoing study of QRX003 for Netherton Syndrome, highlighting significant improvements in skin condition and patient...
Quoin Pharmaceuticals Announces FDA Clearance of Clinical …
Quoin’s innovative pipeline comprises three products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa and others.
- Some results have been removed